Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Status”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Not applicableEnded earlyNCT03619044
What this trial is testing

The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.

Who this might be right for
HER2-positive Breast Cancer
Institut Claudius Regaud 4
Testing effectiveness (Phase 2)Study completedNCT01050322
What this trial is testing

Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.

Who this might be right for
BRMS1Performance Status Zero to Two for Beginning the StudyPatient With a Maximum of One Chemotherapy+1 more
Latin American Cooperative Oncology Group 142
Testing effectiveness (Phase 2)UnknownNCT05619016
What this trial is testing

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Who this might be right for
Esophageal NeoplasmsGastric Neoplasms MalignantBreast Cancer+1 more
Karolinska University Hospital 72
Not applicableLooking for participantsNCT07038928
What this trial is testing

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Who this might be right for
Bladder Cancer
AstraZeneca 600
Not applicableStudy completedNCT05673850
What this trial is testing

Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

Who this might be right for
Breast Neoplasms
Peking University 518
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07126561
What this trial is testing

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Who this might be right for
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
University of Chicago 43
Not applicableNot Yet RecruitingNCT07132502
What this trial is testing

Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 24
Not applicableLooking for participantsNCT06550063
What this trial is testing

HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes

Who this might be right for
Esophagus CancerGastric CancerHER2-positive Cancer+1 more
St. James's Hospital, Ireland 2,188
Large-scale testing (Phase 3)UnknownNCT03423199
What this trial is testing

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Who this might be right for
Breast Neoplasms
National Cancer Center, Japan 180
Large-scale testing (Phase 3)Study completedNCT01942135
What this trial is testing

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Who this might be right for
Metastatic Breast Cancer
Pfizer 521
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939
What this trial is testing

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Who this might be right for
HER2-positive Breast Cancer
Fudan University 288
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Testing effectiveness (Phase 2)Study completedNCT01068704
What this trial is testing

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 4
Testing effectiveness (Phase 2)Study completedNCT02339532
What this trial is testing

Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

Who this might be right for
Breast Cancer
UNICANCER 86
Not applicableLooking for participantsNCT07030569
What this trial is testing

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Who this might be right for
RadiomicRadiomicsBreast Cancer Metastatic+13 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 500
Testing effectiveness (Phase 2)WithdrawnNCT05664893
What this trial is testing

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)

Who this might be right for
HER2 Negative Breast Cancer Not Immediately Operated
Centre Antoine Lacassagne
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322
What this trial is testing

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Who this might be right for
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
UNICANCER 172
Testing effectiveness (Phase 2)Active Not RecruitingNCT07176702
What this trial is testing

A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy

Who this might be right for
Metastatic PDACHER2-positive Status
Shanghai Zhongshan Hospital 45